Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Eiger BioPharmaceuticals stock | $8.76

Own Eiger BioPharmaceuticals stock in just a few minutes.

Fact checked

Eiger BioPharmaceuticals, Inc is a biotechnology business based in the US. Eiger BioPharmaceuticals shares (EIGR) are listed on the NASDAQ and all prices are listed in US Dollars. Eiger BioPharmaceuticals employs 29 staff and has a market cap (total outstanding shares value) of USD$335.4 million.

How to buy shares in Eiger BioPharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Eiger BioPharmaceuticals. Find the stock by name or ticker symbol: EIGR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Eiger BioPharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$8.76, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Eiger BioPharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Eiger BioPharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Eiger BioPharmaceuticals share price

Use our graph to track the performance of EIGR stocks over time.

Eiger BioPharmaceuticals shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$8.76
52-week rangeUSD$4.55 - USD$15.6
50-day moving average USD$9.76
200-day moving average USD$9.9816
Wall St. target priceUSD$31.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.649

Buy Eiger BioPharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Eiger BioPharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Eiger BioPharmaceuticals price performance over time

Historical closes compared with the close of $8.76 from 2020-12-09

1 week (2021-01-11) -24.22%
1 month (2020-12-18) -10.15%
3 months (2020-10-16) -15.61%
6 months (2020-07-17) -6.41%
1 year (2020-01-17) -37.83%
2 years (2019-01-18) -36.57%
3 years (2018-01-18) 8.9
5 years (2016-01-15) 661.74%

Eiger BioPharmaceuticals financials

Gross profit TTM USD$0
Return on assets TTM -29.11%
Return on equity TTM -76.75%
Profit margin 0%
Book value $2.912
Market capitalisation USD$335.4 million

TTM: trailing 12 months

Shorting Eiger BioPharmaceuticals shares

There are currently 1.5 million Eiger BioPharmaceuticals shares held short by investors – that's known as Eiger BioPharmaceuticals's "short interest". This figure is 14.9% down from 1.8 million last month.

There are a few different ways that this level of interest in shorting Eiger BioPharmaceuticals shares can be evaluated.

Eiger BioPharmaceuticals's "short interest ratio" (SIR)

Eiger BioPharmaceuticals's "short interest ratio" (SIR) is the quantity of Eiger BioPharmaceuticals shares currently shorted divided by the average quantity of Eiger BioPharmaceuticals shares traded daily (recently around 686032.43243243). Eiger BioPharmaceuticals's SIR currently stands at 2.22. In other words for every 100,000 Eiger BioPharmaceuticals shares traded daily on the market, roughly 2220 shares are currently held short.

However Eiger BioPharmaceuticals's short interest can also be evaluated against the total number of Eiger BioPharmaceuticals shares, or, against the total number of tradable Eiger BioPharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eiger BioPharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Eiger BioPharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0476% of the tradable shares (for every 100,000 tradable Eiger BioPharmaceuticals shares, roughly 48 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Eiger BioPharmaceuticals.

Find out more about how you can short Eiger BioPharmaceuticals stock.

Eiger BioPharmaceuticals share dividends

We're not expecting Eiger BioPharmaceuticals to pay a dividend over the next 12 months.

Have Eiger BioPharmaceuticals's shares ever split?

Eiger BioPharmaceuticals's shares were split on a 1:15 basis on 23 March 2016. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Eiger BioPharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Eiger BioPharmaceuticals shares which in turn could have impacted Eiger BioPharmaceuticals's share price.

Eiger BioPharmaceuticals share price volatility

Over the last 12 months, Eiger BioPharmaceuticals's shares have ranged in value from as little as $4.55 up to $15.6. A popular way to gauge a stock's volatility is its "beta".

EIGR.US volatility(beta: 1.3)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eiger BioPharmaceuticals's is 1.2951. This would suggest that Eiger BioPharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Eiger BioPharmaceuticals overview

Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site